Salud financiera de hoja de balance de GlaxoSmithKline Pharmaceuticals
Salud financiera controles de criterios 5/6
GlaxoSmithKline Pharmaceuticals tiene unos fondos propios totales de ₹15.4B y una deuda total de ₹0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son ₹32.7B y ₹17.3B respectivamente. GlaxoSmithKline Pharmaceuticals El EBIT de la empresa es de ₹7.7B, por lo que su ratio de cobertura de intereses es de -11.3. Su tesorería e inversiones a corto plazo ascienden a ₹16.1B.
Información clave
1.4%
Ratio deuda-patrimonio
₹213.80m
Deuda
| Ratio de cobertura de intereses | -11.2x |
| Efectivo | ₹16.05b |
| Patrimonio | ₹15.40b |
| Total pasivo | ₹17.31b |
| Activos totales | ₹32.70b |
Actualizaciones recientes sobre salud financiera
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02Recent updates
GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?
Jul 07Análisis de la situación financiera
Pasivos a corto plazo: GLAXOLos activos a corto plazo (₹25.0B) de la empresa superan a sus pasivos a corto plazo (₹14.6B).
Pasivo a largo plazo: GLAXOLos activos a corto plazo (₹25.0B) superan a sus pasivos a largo plazo (₹2.7B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: GLAXO tiene más efectivo que su deuda total.
Reducción de la deuda: GLAXOha pasado de 0.03% a 1.4% en los últimos 5 años.
Cobertura de la deuda: GLAXOLa deuda de la empresa está bien cubierta por el flujo de caja operativo (3222.5%).
Cobertura de intereses: GLAXO gana más intereses de los que paga, por lo que la cobertura del pago de intereses no es preocupante.